



**THE FOUNDATION
FOR SECURE
MARKETS**

#46141

DATE: DECEMBER 11, 2019

SUBJECT: PROTALIX BIOTHERAPEUTICS, INC. – REVERSE SPLIT
OPTION SYMBOL: PLX
NEW SYMBOL: PLX1
DATE: 12/20/19

Protalix BioTherapeutics, Inc. (PLX) has announced a 1-for-10 reverse stock split. As a result of the reverse stock split, each PLX Common Share will be converted into the right to receive 0.10 (New) Protalix BioTherapeutics, Inc. Common Shares. The reverse stock split will become effective before the market open on December 20, 2019.

CONTRACT ADJUSTMENT

Effective Date: December 20, 2019

Option Symbol: PLX changes to PLX1

Contract Multiplier: 1

Strike Divisor: 1

New Multiplier: 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

New Deliverable Per Contract: 10 (New) Protalix BioTherapeutics, Inc. (PLX) Common Shares

CUSIP: PLX (New): 74365A309

PRICING

The underlying price for PLX1 will be determined as follows:

$$PLX1 = 0.10 (PLX)$$

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.